Chengda Bio has received a drug registration certificate for its quadrivalent influenza virus split vaccine from China's National Medical Products Administration. Additionally, the company's subsidiary has received a notice confirming compliance with Good Manufacturing Practice (GMP) standards, indicating readiness for scaled production. The news also mentions STMicroelectronics planning to raise $1.5 billion through convertible bonds and a separate report on Sam's Club headquarters being interviewed regarding food safety issues. AI
RANK_REASON The cluster reports on a regulatory approval for a vaccine, which falls under research and development milestones. [lever_c_demoted from research: ic=1 ai=0.1]
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →